Active Biotech Ab · OMXSTO:ACTI
Active Biotech Ab — Investor Day (November 2020)
15 slides from Active Biotech Ab's investor day presentation, Nov 24, 2020
Slide 1: Laquinimod - Treatment of inflammatory eye disorders
Laquinimod - Treatment of inflammatory eye disorders Capital Markets Day 24 November 2020 Helena Eriksson, CSO
Slide 2: Safe Harbor Statement
Safe Harbor Statement • Certain statements made during the course of this presentation are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the co
Slide 3: Laquinimod - Background
Laquinimod – Background Mode of action • Small molecule immunomodulator Indication • Inflammatory eye disorders Clinical status • Planning of phase 2 Proof-of-Principle study in uveitis, H2 2021 Safety • >5,000 persons exposed, >14,000 person-years of exposure Regulatory • Regulatory package of prec
Slide 4: Uveitis - A severe inflammatory eye disorder and leading cause of blindness
Uveitis – A severe inflammatory eye disorders and the leading cause of blindness Inflammation of the uveal tract with associated inflammation of the adjacent structures such as cornea, sclera, vitreous and retina Symptoms includes Cornea • Decreased vision • Dark floating spots • Eye pain and rednes
Slide 5: Uveitis - Subtypes and today's treatments
Uveitis – Subtypes and todays treatments Laquinimod • Infectious or non-infectious • Location of the inflammation ØLaquinimod will target non-infectious non-anterior uveitis Disease characteristics Todays treatment non-infectious non-anterior uveitis • Affects mostly adults 20-60 yrs 1st Line of tre
Slide 6: Non-infectious non-anterior uveitis - Unmet medical need
Non-infectious non-anterior uveitis – Unmet medical need • About 35 % of the patients suffer from severe visual impairment/blindness • 40 % of the patients fail on steroid therapy • Long-term treatment of steroids in high doses is associated with severe side effects • No topical treatment options ar
Slide 7: Non-infectious non-anterior uveitis - Addressable opportunity as an orphan indication
Non-infectious non-anterior uveitis – Addressable opportunity as an orphan indication Significant opportunity in segment of non-infectious non-anterior uveitis in 7MM, forecasts for 2026 ~ 437 000 Orphan disease in US and EU people Total diagnosed Corticosteroids only effective in 60% prevalent case
Slide 8: Non-infectious uveitis - Pathogenesis
Non-infectious uveitis – Pathogenesis Inflammation and 1. Presentation of antigen to T cells in the periphery tissue damage Antigen 4. Local antigen Antigen recognition, APC Naїve T cell presenting cell production of pro-inflammatory cytokines and chemokines 2. Activation and clonal expansion of T c
Slide 9: Laquinimod Mode-of-action
Laquinimod – Mode-of-action Laquinimod skews antigen presenting cells towards an anti-inflammatory phenotype, resulting in reduction of pro-inflammatory T cells and increase of anti-inflammatory regulatory T cells Antigen Laquinimod APC Naїve T cell 1. Presentation of antigen to T cells Activation o
Slide 10: Shift of balance from pro-inflammatory T cells to regulatory T cells
Laquinimod – Shift of balance from pro-inflammatory T cells to anti-inflammatory regulatory T cells Th1 cells Th17 cells Treg cells Abbr: veh – Vehicle, laq - laquinimod, IFN-γ – interferon-gamma, IL – interleukin, CD – cluster of differentiation, Foxp3 – forkhead box P3, T reg-Regulatory T cell, Th
Slide 11: Oral laquinimod is a potent inhibitor of experimental uveitis
Laquinimod – Oral administered laquinimod is a potent inhibitor of experimental uveitis Abstract Study design Experimental autoimmune uveitis (EAU) model in C57BL/6J mice. Immunization with the uveitogenic antigen, IRBP 651– 670. Oral laquinimod treatment from day 0 or day 7, relative to immunizatio
Slide 12: Topical administration of laquinimod reduces clinical manifestation of experimental uveitis
Laquinimod – Topical administration of laquinimod reduces clinical manifestation of experimental uveitis Experimental acute uveitis (EAU) Decreased inflammation in the anterior Decreased inflammation in the part of the eyes posterior part of the eye Histological ocular evaluation Ocular examination
Slide 13: Laquinimod development program for Uveitis
Laquinimod development program for Uveitis – Advancing the clinical program using existing capsule formulation • Full commercial scale CMC documentation available • Safety data from > 5,000 exposed persons • Full IND regulatory documentation available • Substantial pre-clinical proof-of-principle •
Slide 14: Laquinimod activities through 2023
Laquinimod – activities through 2023 2020 2021 H1 2021 H2 2022 H1 2022 H2 2023 ü Partnership with • Preclinical local Ph2-oral: Ph1-topical Ph2-oral Leukocare AG tolerance Start Readout safety Readout proof-of- LAQUINIMOD established principle • Manufacturing of Ph1- topical ü Development of clinica
Slide 15: www.activebiotech.com
www.activebiotech.com